SAIF Invests In China’s Pharmaceutical Industry
This article was originally published in PharmAsia News
ShenZhen Hybio Engineering has received an initial injection of $15 million venture capital from SAIF Partners and Shenzhen Capital Group. As a veteran in peptide R&D and marketing, Hybio enjoys the biggest peptide drug market share in China; it recently passed FDA's on-site audit in February 2007. The company revealed that the fund will be used in R&D for peptide drugs as well as in opening up international markets. Hybio represents SAIF's first investment in China's pharmaceutical industry and the private equity firm is optimistic of the industry's rapid growth opportunities arising from China's health care reform. It is currently in discussion with a Shanghai biomedical reagent producer. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.